Back to top
more

Revance Therapeutics (RVNC)

(Real Time Quote from BATS)

$3.69 USD

3.69
1,034,330

+0.03 (0.82%)

Updated Apr 23, 2024 03:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

General Information

Revance Therapeutics, Inc

1222 DEMONBREUN STREET SUITE 2000

NASHVILLE, TN 37203

Phone: 615-724-7755

Fax: 510-742-3401

Web: http://www.revance.com

Email: jessica.serra@revance.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/14/2024

EPS Information

Current Quarter EPS Consensus Estimate -0.66
Current Year EPS Consensus Estimate -2.17
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/14/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 3.66
52 Week High 37.98
52 Week Low 3.61
Beta 1.05
20 Day Moving Average 1,472,047.88
Target Price Consensus 16.20

RVNC

% Price Change
4 Week -21.72
12 Week -39.74
YTD -58.59
% Price Change Relative to S&P 500
4 Week -18.48
12 Week -40.73
YTD -60.58
Share Information
Shares Outstanding (millions) 104.22
Market Capitalization (millions) 379.35
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 65.93%
vs. Previous Quarter 16.22%
   
Sales Growth
vs. Previous Year 39.82%
vs. Previous Quarter 22.94%
   
Price Ratios
Price/Book NA
Price/Cash Flow NA
Price / Sales 1.62
ROE
3/31/24 NA
12/31/23 NA
9/30/23 NA
ROA
3/31/24 NA
12/31/23 -45.78
9/30/23 -59.67
Current Ratio
3/31/24 NA
12/31/23 3.80
9/30/23 4.73
Quick Ratio
3/31/24 NA
12/31/23 3.29
9/30/23 4.17
Operating Margin
3/31/24 NA
12/31/23 -105.46
9/30/23 -157.39
Net Margin
3/31/24 NA
12/31/23 -138.43
9/30/23 -193.42
Pre-Tax Margin
3/31/24 NA
12/31/23 -138.30
9/30/23 -193.28
Book Value
3/31/24 NA
12/31/23 -1.73
9/30/23 -1.21
Inventory Turnover
3/31/24 NA
12/31/23 1.93
9/30/23 2.54
Debt-to-Equity
3/31/24 NA
12/31/23 NA
9/30/23 NA
Debt to Capital
3/31/24 NA
12/31/23 NA
9/30/23 NA